非典型与恶性脑膜瘤的实验性治疗现状
本文综述1980至2020年间的临床前与临床证据,聚焦靶向治疗、免疫治疗及新技术用于非典型(WHO II级)和恶性(WHO III级)脑膜瘤的探索。这类肿瘤术后与放疗后复发率高,分子测序揭示了新通路与药物靶点,多项临床试验正在招募,联合治疗已显示临床获益迹象,结局改善可能即将到来。
要点
- 非典型与恶性脑膜瘤术后及放疗后复发率高,亟需辅助治疗。
- 分子测序揭示新通路与靶点,靶向与免疫治疗临床试验正在开展。
- 已有临床研究提示联合治疗对难治性肿瘤具有临床获益。
核心结论
- 随着多项针对高级别脑膜瘤的临床试验活跃开展,这类肿瘤的结局有望取得实质性改善。
研究设计与样本
- 综述类:检索1980至2020年关于高级别脑膜瘤新兴治疗的临床前与临床证据文献,并纳入同期临床试验。
主要发现
- 本文讨论的新兴治疗在临床前证据方面令人鼓舞。
- 多项临床试验正在招募患者,以推动脑膜瘤靶向分子治疗的转化。
- 多项临床研究提示联合治疗对这类难治性肿瘤具有临床获益。
临床怎么用
- 对术后及放疗后复发风险高的非典型与恶性脑膜瘤,可关注靶向、免疫及联合治疗的临床试验机会。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Atypical (WHO grade II) and malignant meningiomas (WHO Grade III) are a rare subset of primary intracranial tumors. Given their relatively high recurrence rate after surgical resection and radiotherapy, there has been a recent push to explore other adjuvant treatment options for these treatment-refractory tumors. Recent advances in molecular sequencing of tumors have elucidated new pathways and drug targets which are currently being studied. This article provides a thorough overview of novel investigational therapeutics including targeted therapy, immunotherapy, and new technological modalities for atypical and malignant meningiomas. METHODS: We performed a comprehensive review of the available literature regarding preclinical and clinical evidence for emerging treatments for high grade meningiomas from 1980 to 2020 including contemporaneous clinical trials. RESULTS: There is encouraging preclinical evidence regarding the efficacy of the emerging treatments discussed in this article. Several clinical trials are currently recruiting patients to translate targeted molecular therapy for meningiomas. Several clinical studies have suggested a clinical benefit of combinatorial treatment for these treatment-refractory tumors. CONCLUSION: With numerous active clinical trials for high grade meningiomas, a meaningful improvement in the outcomes for these tumors may be on the horizon.
引用
- Corona AM, Di L, Shah AH, et al. Current experimental therapies for atypical and malignant meningiomas. J Neurooncol. 2021. PMID: 33950341. doi:10.1007/s11060-021-03759-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。